The portable neuromodulation stimulator (PoNS), a noninvasive device that’s approved to improve walking and balance in people with…
Articles by Andrea Lobo, PhD
Exposure to higher levels of ground-level ozone may significantly increase the risk that children and teens will develop multiple…
The European Medicines Agency (EMA) has granted PRIME designation to Oculis‘ experimental treatment privosegtor for optic neuritis,…
Quantum Biopharma has officially filed with the U.S. Food and Drug Administration (FDA) for clearance to begin a Phase…
MS Canada is inviting cyclists across the country to take part in its 2026 MS Bike season, a series…
More than 70% of people with multiple sclerosis (MS) receiving outpatient rehabilitation take at least five medications — often…
IMP761, an experimental immunosuppressive therapy being developed by Immutep for multiple sclerosis (MS) and other autoimmune diseases, was…
An experimental therapy designed to eliminate harmful B-cells — key drivers of inflammation in multiple sclerosis (MS) and other…
The National Multiple Sclerosis Society has designated UC Davis Health in California as a new Center for Comprehensive MS…
Innocare Pharma has dosed the first healthy volunteer in a clinical trial in China testing ICP-538, its oral treatment…
People with multiple sclerosis (MS) who experience their first symptoms after age 50 tend to have faster disability progression than…
Immunic Therapeutics has been granted a new patent in Europe covering multiple dosing regimens of its experimental therapy…
People with multiple sclerosis (MS) are about twice as likely to develop restless legs syndrome (RLS) — a…
A researcher at the Walter and Eliza Hall Institute in Australia has received funding from MS Australia to uncover…
A Phase 1 clinical trial testing azercabtagene zapreleucel (azer-cel), TG Therapeutics’ CAR-T-cell therapy, in progressive forms of multiple…
People with multiple sclerosis (MS) have a nearly fivefold increased risk of developing dementia compared with those without the…
Merck and Mayo Clinic have launched a research collaboration to use artificial intelligence (AI) and large-scale clinical data…
Canary Speech and Intermountain Ventures are collaborating to test whether subtle changes in a person’s voice can help identify…
MS Canada is hosting its annual MS Read-a-Thon, a fundraiser encouraging children to turn their reading goals into donations to…
Teva Canada and Novartis Canada formed a partnership to ensure continued access to Mayzent (siponimod) for people in Canada…
People with multiple sclerosis (MS) reported improvements in physical and mental quality of life along with reduced depression after…
Taking part in a six-week yoga program improved self-reported physical activity and sleep quality, and reduced fatigue among people…
Bionxt Solutions’ experimental sublingual therapy BNT23001 led to about 40% higher blood exposure to cladribine than a conventional…
Brenig Therapeutics has launched an early Phase 1 clinical trial to evaluate its experimental small molecule BT-409Â in healthy…
Taking oral caffeine supplements may significantly reduce fatigue and improve quality of life and mood in people with multiple…
Evogene and Unravel Biosciences are collaborating to develop a new class of therapies…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to privosegtor, an experimental treatment from Oculis…
Gadoquatrane, a contrast agent Bayer is developing for MRI scans, showed similar safety and pharmacokinetic (PK) profiles — meaning…
The U.S. Food and Drug Administration (FDA) has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent (siponimod),…
Aquatic therapy significantly eased fatigue and improved balance in multiple sclerosis (MS) patients in a clinical trial in Greece,…